Italfarmaco S.p.A. today announced a comprehensive update on the regulatory and clinical advancements for givinostat, the ...

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced. COPENHAGEN ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, ...

AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...

The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.

Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart biosimilar.

The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...